Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer
International Journal of Clinical Oncology · 2025
DOI: 10.1007/s10147-024-02681-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Tokiyoshi Tanegashima und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
- Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. shiota.masaki.101@m.kyushu-u.ac.jp.
- Department of Urology, Miyazaki University, Miyazaki, Japan.
- Department of Urology, Niigata Cancer Center Hospital, Niigata, Japan.
- Department of Urology, Harasanshin Hospital, Fukuoka, Japan.
- Department of Urology, Shizuoka General Hospital, Shizuoka, Japan.
Zitieren
APA
Tanegashima, T., Shiota, M., Terada, N., Saito, T., Yokomizo, A., Kohei, N., Goto, T., Kawamura, S., Hashimoto, Y., Takahashi, A., Kimura, T., Tabata, K. I., Tomida, R., Hashimoto, K., Sakurai, T., Shimazui, T., Sakamoto, S., Kamiyama, M., Tanaka, N., …, & Japanese Urological Oncology Group (2025). Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02681-2
Vancouver
Tanegashima T, Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, et al. Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-024-02681-2
BibTeX
@article{Tanegashima2025,
author = {Tanegashima, Tokiyoshi and Shiota, Masaki and Terada, Naoki and Saito, Toshihiro and Yokomizo, Akira and Kohei, Naoki and Goto, Takayuki and Kawamura, Sadafumi and Hashimoto, Yasuhiro and Takahashi, Atsushi and Kimura, Takahiro and Tabata, Ken-Ichi and Tomida, Ryotaro and Hashimoto, Kohei and Sakurai, Toshihiko and Shimazui, Toru and Sakamoto, Shinichi and Kamiyama, Manabu and Tanaka, Nobumichi and Mitsuzuka, Koji and Kato, Takuma and Narita, Shintaro and Yasumoto, Hiroaki and Teraoka, Shogo and Kato, Masashi and Osawa, Takahiro and Nagumo, Yoshiyuki and Matsumoto, Hiroaki and Enokida, Hideki and Sugiyama, Takayuki and Kuroiwa, Kentaro and Kitamura, Hiroshi and Kamoto, Toshiyuki and Eto, Masatoshi and Japanese Urological Oncology Group, Japanese Urological Oncology Group},
title = {Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer},
journal = {International Journal of Clinical Oncology},
year = {2025},
doi = {10.1007/s10147-024-02681-2}
}
EUVIMED